Inozyme Pharma Statistics

Total Valuation

Inozyme Pharma has a market cap or net worth of $258.69 million. The enterprise value is $220.87 million.

Market Cap	258.69M
Enterprise Value	220.87M

Important Dates

The next estimated earnings date is Tuesday, August 5, 2025, before market open.

Earnings Date	Aug 5, 2025
Ex-Dividend Date	n/a

Share Statistics

Inozyme Pharma has 64.92 million shares outstanding. The number of shares has increased by 12.58% in one year.

Current Share Class	64.92M
Shares Outstanding	64.92M
Shares Change (YoY)	+12.58%
Shares Change (QoQ)	+0.05%
Owned by Insiders (%)	0.78%
Owned by Institutions (%)	41.85%
Float	30.17M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	8.08
P/TBV Ratio	8.14
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.19, with a Debt / Equity ratio of 1.48.

Current Ratio	2.19
Quick Ratio	1.98
Debt / Equity	1.48
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-18.70

Financial Efficiency

Return on equity (ROE) is -141.69% and return on invested capital (ROIC) is -53.98%.

Return on Equity (ROE)	-141.69%
Return on Assets (ROA)	-48.45%
Return on Invested Capital (ROIC)	-53.98%
Return on Capital Employed (ROCE)	-201.35%
Revenue Per Employee	n/a
Profits Per Employee	-$1.59M
Employee Count	67
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -13.37% in the last 52 weeks. The beta is 2.29, so Inozyme Pharma's price volatility has been higher than the market average.

Beta (5Y)	2.29
52-Week Price Change	-13.37%
50-Day Moving Average	2.42
200-Day Moving Average	2.83
Relative Strength Index (RSI)	83.48
Average Volume (20 Days)	1,435,979

Short Selling Information

The latest short interest is 3.68 million, so 5.67% of the outstanding shares have been sold short.

Short Interest	3.68M
Short Previous Month	3.84M
Short % of Shares Out	5.67%
Short % of Float	12.20%
Short Ratio (days to cover)	0.75

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-105.47M
Pretax Income	-88.56M
Net Income	-106.72M
EBITDA	-104.74M
EBIT	-105.47M
Earnings Per Share (EPS)	-$1.68

Full Income Statement

Balance Sheet

The company has $84.78 million in cash and $46.95 million in debt, giving a net cash position of $37.82 million or $0.58 per share.

Cash & Cash Equivalents	84.78M
Total Debt	46.95M
Net Cash	37.82M
Net Cash Per Share	$0.58
Equity (Book Value)	31.80M
Book Value Per Share	0.49
Working Capital	50.86M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$96.52 million and capital expenditures -$30,000, giving a free cash flow of -$96.55 million.

Operating Cash Flow	-96.52M
Capital Expenditures	-30,000
Free Cash Flow	-96.55M
FCF Per Share	-$1.49

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Inozyme Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-12.58%
Shareholder Yield	-12.58%
Earnings Yield	-41.25%
FCF Yield	-37.32%

Analyst Forecast

The average price target for Inozyme Pharma is $15.22, which is 281.93% higher than the current price. The consensus rating is "Buy".

Price Target	$15.22
Price Target Difference	281.93%
Analyst Consensus	Buy
Analyst Count	9
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	2